Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FreMRI: Fremanezumab MRI Study in Migraine
NCT06244823Phase 4Recruiting
- Sponsor
- Hospital Clínico Universitario de Valladolid
- Start
- Mar 2023
- Primary completion
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of fremanezumab in migraine, sponsored by Hospital Clínico Universitario de Valladolid. Started Mar 2023; status: recruiting.
02
Drugs
fremanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT06244823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06244823.